Xience V at WFUBMC: Real World Outcomes Using Second Generation DES.

Trial Profile

Xience V at WFUBMC: Real World Outcomes Using Second Generation DES.

Completed
Phase of Trial: Phase IV

Latest Information Update: 08 Nov 2017

At a glance

  • Drugs Everolimus (Primary) ; Paclitaxel; Sirolimus
  • Indications Acute coronary syndromes; Coronary artery disease; Coronary artery restenosis; Myocardial infarction
  • Focus Adverse reactions
  • Most Recent Events

    • 07 Oct 2013 Status changed from recruiting to completed.
    • 23 Oct 2012 Planned End Date changed to 1 Dec 2010 as reported in the abstract presented at the 24th Annual Scientific Symposium on Transcatheter Cardiovascular Therapeutics..
    • 23 Oct 2012 Planned initiation date changed to 1 Jul 2007 as reported in the abstract presented at the 24th Annual Scientific Symposium on Transcatheter Cardiovascular Therapeutics..
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top